Dean has built up a wealth of knowledge on the global generics and biosimilar medicines industries in his five years with Generics bulletin. He specializes in commercial and legal issues, writing in-depth analyses of corporate strategy and getting under the skin of patent-infringement proceedings and other litigation. He attends investor and regulatory meetings with business leaders, favoring the investor days with their focus on corporate strategy. In his spare time, Dean enjoys visiting museums and playing five-a-side football.
Latest From Dean Rudge
Acknowledging that “different companies have different views and approaches about interchangeability,” Samsung Bioepis has once again called into question the controversial designation.
Endo’s non-injectable Generics revenues plunged by 28% in Q1, in part due to competitive challenges in the US generics sector that management said would continue through 2021.
Amid continued debate over biosimilar interchangeability in the US, Viatris has said it expects to pick up the first such approvals later this year with the company’s insulin glargine and insulin aspart biosimilar products.
Committed to greater transparency following its formation in November, Viatris published first-quarter financial results that met top- and bottom-line expectations. However, the US-based company promised to update the market for meeting revenue projections in 2021.
Coherus BioSciences aims to have four biosimilars on the market by 2023, including ranibizumab and bevacizumab for which it has provided updated timelines for planned US Food and Drug Administration filings.
Fresenius Kabi discussed the latest around the potential of an FDA warning letter at its key injectables plant in Melrose Park, after earlier this year confirming that no product launches from the site were anticipated in 2021.